July 2008 (revised 7.14.08)

Study Type	Acute Coronary Syndrome
Title	Appraise-Apixaban for Prevention of Acute Ischemic Safety Events
Study Aim	Evaluate safety (bleeding) of 4 doses of apixaban as compared to placebo over a 26 week treatment period in selected subjects with recent (< 7 days) ACS.  Determine optimal dose and regimen of apixaban for use in Phase 3 ACS trial.

Study Type	Acute Coronary Syndrome
Title	Avant Garde-To Evaluate the Efficacy of Aliskiren and Valsartan Versus Placeboon Lowering Levels of NT-proBNP in Stabilized Patients Post-ACS.
Study Aim	Determine whether aliskiren reduces the levels of NT-proBNP from baseline to week 8 as compared to placebo. Second objective is to determine whether the combination of aliskiren and valsartan reduces the levels of NT-proBNP from baseline to week 8 as compared to each individual monotherapy and placebo.

Study Type	Acute Coronary Syndrome
Title	Improve It-Improved Reduction of Outcomes:  Vytorin Efficacy International Trial
Study Aim	Establish the clinical benefit of Vytorin (Ezetimibe/Simvastatin tablet) versus Simvastatin monotherapy in high-risk subjects presenting with Acute Coronary Syndrome.

Study Type	Acute Coronary Syndrome-Unstable Angina and non-ST Elevation MI
Title	Current-Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions
Study Aim	Determine whether a high dose regimen of clopidogrel (600 mg loading dose followed by 150 mg once daily from day 2 to 7, then 75 mg daily) in preventing  the composite of cardiovascular death, MI or stoke and/or the composite of cardiovascular death, MI, recurrent ischemia or stroke in patients with non-ST segment ACS who are treated with an early invasive strategy with the intent to perform PCI as early as possible within 24 hours of randomization.

Study Type	Arthritis and Coronary Vascular Disease
Title	Precision-Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naprosyn
Study Aim	Compare the effects of the Cox-2-selective inhibitor Celebrex with those of the traditional NSAIDs (ibuprofen and naproxyn) on CV events in patients with osteoarthritis or rheumatoid arthritis who have or are at high risk for CVD.

Study Type	Atrial Fibrillation
Title	Omacor-Assess the Efficacy and Safety of Omacor® for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
Study Aim	Assess the effect of Omacor® (Omega-3-acid ethyl esters) on time to first symptomatic recurrence of atrial fibrillation in subjects with paroxysmal atrial fibrillation.  Time will be measured as event-free days from the first dose of study drug to the first symptomatic recurrence of atrial fibrillation.

Study Type	Atrial Fibrillation
Title	Rocket-Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Embolism in Subjects with Non-Valvular Atrial Fibrillation
Study Aim	Demonstrate that the efficacy or rivaroxaban, a direct Fxa inhibitor, is non-inferior to that of dose-adjusted warfarin for the prevention of thromboembolic events in subjects with non-valvular atrial fibrillation as measured by the composite of stroke and non-central nervous system systemic embolism.

Study Type	Coronary Artery Bypass
Title	Glutamine- Effect of glutamine on heat shock protein expression and metabolic state in human myocardial tissue
Study Aim	Pre-operative glutamine therapy will attenuate myocardial injury during CABG as measured by coronary effluent and plasma troponin and creatinine phosphokinase release.

Study Type	Device Registry
Title	Optimum-Optim™ Lead Insulation Material Registry
Study Aim	Produce a prospective, outcome-oriented registry of patients implanted with SJM Optim™ leads.  This registry will evaluate the chronic clinical performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optim™ insulation material.

Study Type	Device study (ICD)
Title	Right-Rhythm ID Going Head-to-head Trial
Study Aim	Assess VT/VF arrhythmia discrimination in Guidant (Rhythm ID™) versus Medtronic (Enhanced PR Logic™ and Wavelet™) ICDs by comparing the time to first inappropriate VT/VF therapy after the pre-discharge visit.  Inappropriate VT/VF therapy is defined as a VT/VF therapy delivered for a SVT event.

Study Type	PACEMAKER
Title	PACEmakers and Beta-blocker Therapy after Myocardial Infarction (PACE-MI)
Study Aim	Investigate whether pacemaker facilitated beta-blocker therapy after MI reduces the combined endpoint of total mortality & non-fatal reinfarction in a subgroup of post MI patients who currently do not routinely receive beta-blocker therapy.

Study Type	Patent Foramen Ovale and Crytogenic Stroke
Title	RESPECT-Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment
Study Aim	Investigate whether percutaneous PFO closure is superior to current standard of care (medical treatment) in the prevention of recurrent embolic stroke or transient ischemic attacks as evaluated by:  non-fatal stroke, periprocedural death and fatal stroke.

Study Type	Patent Foramen Ovale Closure and Recurrent Stroke Registry
Title	PFO Access Registry–Patent Foramen Ovale Closure with the Amplatzer PFO Occluder Device in Patients with Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy
Study Aim	Allow access to the Amplatzer PFO Occluder device in subjects with a PFO who have already experienced at least 2 cryptogenic strokes due to presumed paradoxical embolism through patent foramen ovale and who have failed conventional drug therapy.  Information from this registry may be considered as supportive in conjunction with data from ongoing RESPECT randomized clinical trial.